The rising adoption of acne treatments, strong product pipeline, and adoption of a sedentary lifestyle are the major drivers for the global professional acne treatment market. Due to the aforesaid factors, the industry is expected to generate $13,124.5 million revenue in 2030, advancing at a CAGR of 7.6% during 2020–2030.
Due to the COVID-19 pandemic, governments had enacted a number of regulations all over the world, such as lockdowns and social distancing. Due to these measures, the supply chain and manufacturing, including those of acne treatment products, were negatively impacted. In the near future, with the lifting of the lockdowns, the market is expected to revive, as the demand for acne treatments, including drugs and devices, increases.
The professional acne treatment market is categorized into inflammatory and non-inflammatory, on the basis of acne type. Of these, the inflammatory bifurcation dominated the market during the historical period (2014–2020), and it is expected to maintain its dominance during the forecast period (2021–2030). As inflammatory acne is often bothersome, patients seek to get rid of it as soon as possible, which is largely attributed to the rapid and effective treatments available.
Moreover, the professional acne treatment market is categorized into drugs and devices, on the basis of treatment type. Of these, devices are expected to witness the faster growth during the forecast period. This will primarily be due to an increase in the use of laser and light-based acne treatments, notably in developed economies, as a result of drugs’ adverse effects.
North America was the largest contributor to the professional acne treatment market in 2020. This is mainly attributed to the proliferating demand for treatments due to the escalating prevalence of acne and presence of numerous established players in the region. In addition, the growing awareness of newly produced drugs and high disposable income contribute to the regional market growth.
The Asia-Pacific (APAC) market is expected to witness the fastest growth during the forecast period due to the increasing disposable income leading to a higher adoption of skincare products, including for acne treatment. Furthermore, the increasing awareness on improved appearance and reasonable cost of laser treatments and devices are the major factors driving the APAC market.
Players in the professional acne treatment market have been involved in mergers & acquisitions and collaborations to remain competitive. For instance, in September 2020, CHEPLAPHARM Arzneimittel GmbH acquired the Zineryt brand from LEO Pharma A/S to expand its product portfolio in several countries, including Russia, France, Saudi Arabia, the U.K., Poland, and Italy.
Moreover, in June 2021, Sol-Gel Technologies Ltd., a clinical-stage dermatology company, and Galderma SA announced two exclusive five-year license agreements for the commercialization of EPSOLAY and TWYNEO in the U.S. Under these agreements, Galderma has an exclusive license to commercialize Sol-Gel’s advanced investigational drug products: EPSOLAY (benzoyl peroxide [5.0%] cream), which is under investigation for the treatment of inflammatory lesions, and TWYNEO (benzoyl peroxide [3.0%] and tretinoin [0.1%] cream), which is under investigation for the treatment of acne vulgaris.
The major players operating in the global professional acne treatment market are Galderma SA, Johnson & Johnson, Bausch Health Companies Inc., Pfizer Inc., CHEPLAPHARM Arzneimittel GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Bayer AG, Perrigo Company plc, Almirall S.A., Lumenis Ltd., Candela Corporation, Alma Lasers Ltd., Cutera Inc., Sciton Inc., EL.EN. S.p.a., Fotona d.o.o., Venus Concept Inc., Erchonia Corporation, and InMode Ltd.